SOURCE: Medistem Inc.

Medistem Inc.

December 22, 2010 01:51 ET

Link Between Inflammation and Heart Failure Identified

Possible Mechanism of Action of Medistem's Stem Cell Product in Heart Failure

SAN DIEGO, CA--(Marketwire - December 22, 2010) - Medistem Inc. (PINKSHEETS: MEDS), in collaboration with Dr. Wei-Ping Min's laboratory from the University of Western Ontario, Canada, disclosed results that a molecule typically associated with inflammation, called "toll like receptor (TLR)-4," causes direct killing of heart cells and may be a major contributor to the development of heart failure in patients with diabetes. 

The peer-reviewed publication, which may be accessed from this link http://www.translational-medicine.com/content/pdf/1479-5876-8-133.pdf, showed that hearts of diabetic mice possess increased levels of TLR-4, as compared to hearts from non-diabetic mice. 

Using a technique called "short interfering RNA" (siRNA), the investigators were able to artificially reduce levels of TLR-4. This prevented death of heart cells in diabetic mice. Inflammation associated with the diabetic state is believed to be the cause of increased TLR-4. Chemicals produced by stem cells that suppress inflammation are known to also reduce levels of TLR-4. 

"Medistem's Endometrial Regenerative Cell (ERC) stem cell product possesses potent anti-inflammatory activity. The finding that TLR-4 acts as a bridge between inflammation and heart damage suggests one possible molecular pathway by which the Endometrial Regenerative Cells may be functioning," said Dr. Wei-ping Min, of the University of Western Ontario. "This is very interesting since Medistem and other groups have described the potential of ERC to treat heart failure."

In April of 2010, Medistem published in the peer-reviewed journal, the International Archives of Medicine, the case of a 74 year old man who was treated with intravenous ERC. The patient's ejection fraction, which reflects the heart's pumping activity, increased from 25-30% pre-treatment to 40%. The increase was maintained when the patient was re-examined a year later. Substantial quality of life improvement was noted as assessed by the Minnesota Quality of Life Questionnaire Score which decreased from 97 pre-treatment to 2. No treatment-associated adverse events were noted during the follow-up. The paper is available at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf

Menstrual blood stem cells were also demonstrated by the Japanese group of Hida et al. to improve heart function in mice after experimental infarcts. The paper, which cites Medistem's original ERC discovery (reference 16, Meng et al), was published in the journal Stem Cells and is available at http://onlinelibrary.wiley.com/doi/10.1634/stemcells.2007-0826/pdf.

"Through working with top-notch researchers such as Dr. Wei-ping Min, Medistem is seeking to identify molecular mechanisms by which our universal donor cell therapy product mediates its therapeutic effects," said Vladimir Bogin, MD, Chairman of Medistem Inc and Co-author of the publication. "By understanding the biological effects of our new stem cells, we aim to create quantitative methods of assessing patient responses, which are a fundamental component of successfully developing a stem cell product through the FDA regulatory process."

Medistem has filed an IND with the FDA for treatment of critical limb ischemia using its ERC product. Currently the company is in the process of addressing questions raised by the FDA and anticipates initiating a trial at Indiana University in the First Quarter of 2011.

ERC can be purchased for research use through the company General Biotechnology LLC at the website http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.

Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Vladimir Bogin, MD
    Chairman of the Board
    Medistem Inc.
    9255 Towne Centre Drive
    Suite 450
    San Diego
    CA 92122
    858 349 3617
    858 642 0027

Webosphere

Keyword Cloud

View Website